Immunoglobulin News and Research

RSS

Novel universal flu vaccine confers protection against different strains and subtypes of influenza A viruses

A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged populations, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

30 Jun 2022

How to develop an "all-variant" COVID vaccine

In a recent study published in Nature Immunology, researchers summarized their observations of humoral immune responses elicited in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infected people. Additionally, they discussed all the types of SARS-CoV-2 infection- and vaccine-induced neutralizing antibodies (nAbs).

30 Jun 2022

Casirivimab/imdevimab improve outcomes in early COVID-19

A new Viruses study determines the effect of casirivimab/imdevimab on IFN-1 and cytokines during SARS-CoV-2 infection.

29 Jun 2022

COVID-19 pandemic linked to lower antibodies in breastmilk

New research describes the results of a study measuring such protection and exploring the effects of waning antibody levels on infant susceptibility to respiratory pathogens.

29 Jun 2022

Epigenome-wide DNA methylation patterns in convalescent COVID-19 subjects

Researchers investigated the epigenetic rewiring of odor perception in SARS-CoV-2-infected cells.

29 Jun 2022

Study explores antibody responses following three COVID vaccine doses in kidney transplant recipients

In a recent study posted to the medRxiv* pre-print server, Canadian researchers evaluated antibody responses in kidney transplant recipients (KTRs) before and one and three months after receiving the third dose of a messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine.

28 Jun 2022

BNT162b2 COVID vaccine stimulates significant antibody response in lung cancer patients

In a recent article posted to the medRxiv* preprint server, scientists from Japan assessed the safety and immunogenicity of coronavirus disease 2019 (COVID-19) BNT162b2 vaccine among lung cancer patients under treatment.

28 Jun 2022

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* pre-print server, researchers in the United States described a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) SP1-77 that broadly neutralized its multiple variants of concern (VOCs).

28 Jun 2022

The potential of DNA-based SARS-CoV-2 vaccine candidates

Researchers evaluated the immunogenicity of DNA-based candidate vaccines against SARS-CoV-2 in mice.

28 Jun 2022

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A recent study by scientists at Celentyx Ltd, the University of Birmingham, and the University of Warwick and posted to the bioRxiv* preprint server illustrated a cell-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein attachment assay.

28 Jun 2022

A cancer patient who had SARS-CoV-2 for over eight months

In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

28 Jun 2022

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Researchers presented the PREVENT-19 phase 3 trial findings on the effectiveness of the NVX-CoV2373 adjuvanted, recombinant S nanoparticle vaccine.

27 Jun 2022

Serologic testing captures missed children at risk for long Covid

A new study provides evidence of the utility of serologic testing in helping to pick up children with long Covid following missed diagnoses of COVID-19.

24 Jun 2022

Natural and hybrid immunity dynamics in South African mothers

Researchers evaluated natural and hybrid immunity after four COVID-19 waves in South Africa.

24 Jun 2022

Epstein-Barr virus can reactivate in long COVID

In a recent study posted to the medRxiv* preprint server, researchers at the University of California, San Francisco, and Monogram Biosciences examined the connections between the post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC) and Epstein-Barr virus (EBV) reactivation.

23 Jun 2022

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

A recent article posted to the bioRxiv* preprint server identified numerous efficacious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies from convalescent SARS-CoV-2 patients.

23 Jun 2022

Correlates of anamnestic humoral immunity throughout SARS-CoV-2 variants of concern

A recent work posted to the bioRxiv* preprint server assessed the indicators of anamnestic humoral immunity among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).

23 Jun 2022

A longitudinal population-based study of COVID-19 in the UK

In a recent study posted to the medRxiv* pre-print server, researchers identified potential risk factors and incident symptoms of coronavirus disease 2019 (COVID-19) in the general population of the United Kingdom (UK).

21 Jun 2022

Researchers compare the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection

Researchers comparatively assessed the generation of B lymphocyte-mediated antibody responses and T lymphocyte-mediated cellular responses between mRNA BNT162b vaccinees and mild COVID-19 patients.

21 Jun 2022

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

A new study reported four cases of Myelin Oligodendrocyte Glycoprotein-Associated Disorder that commenced after SARS-CoV-2 infection.

21 Jun 2022

Immunoglobulin News and Research

Novel universal flu vaccine confers protection against different strains and subtypes of influenza A viruses

How to develop an "all-variant" COVID vaccine

Casirivimab/imdevimab improve outcomes in early COVID-19

COVID-19 pandemic linked to lower antibodies in breastmilk

Epigenome-wide DNA methylation patterns in convalescent COVID-19 subjects

Study explores antibody responses following three COVID vaccine doses in kidney transplant recipients

BNT162b2 COVID vaccine stimulates significant antibody response in lung cancer patients

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

The potential of DNA-based SARS-CoV-2 vaccine candidates

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A cancer patient who had SARS-CoV-2 for over eight months

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Serologic testing captures missed children at risk for long Covid

Natural and hybrid immunity dynamics in South African mothers

Epstein-Barr virus can reactivate in long COVID

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

Correlates of anamnestic humoral immunity throughout SARS-CoV-2 variants of concern

A longitudinal population-based study of COVID-19 in the UK

Researchers compare the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News